文献速递腹部MR

钆塞酸增强MRI肝细胞癌新诊断标准的回顾性验证:肝胆期低信号能否借助辅助征象替代廓清

Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features?
PubMed 文献 · Eur Radiol · 2018-09-25

本研究回顾性纳入288例高危患者共387个结节,在钆塞酸增强MRI上比较四种以肝胆期低信号替代廓清的肝细胞癌诊断标准。结果显示,包含肝胆期低信号的标准3和标准4敏感度显著高于仅用门静脉期或移行期低信号的标准,且标准4在排除良性或非肝细胞癌恶性结节后特异度显著高于标准3。

要点

  • 肝胆期低信号可作为廓清的替代,联合辅助征象诊断肝细胞癌敏感度达92.5%。
  • 排除LR-1/2/M结节后,标准4特异度87.4%,显著高于标准3的48.4%。
  • 标准4特异度与标准2(86.3%)相当,但低于标准1(97.9%)。

核心结论

  • 在钆塞酸增强MRI无创诊断肝细胞癌时,肝胆期低信号可替代廓清,在依据特征性影像表现排除良性或非肝细胞癌恶性结节后,可实现高敏感度诊断且特异度损失较小。

研究设计与样本

  • 回顾性研究,纳入288例肝细胞癌高危患者共387个结节(肝细胞癌292个,非肝细胞癌95个),所有结节在钆塞酸增强MRI上表现为动脉期高增强且直径≥1 cm。

关键影像表现/征象

  • 肝细胞癌诊断标准1为动脉期高增强加门静脉期低信号。
  • 标准2为动脉期高增强加门静脉期和/或移行期低信号。
  • 标准3为动脉期高增强加门静脉期和/或移行期和/或肝胆期低信号。
  • 标准4为标准3基础上结合辅助征象并排除LI-RADS v2017中的LR-1/2/M。

诊断标准与关键数值

  • 标准1敏感度70.9%,特异度97.9%。
  • 标准2敏感度86.6%,特异度86.3%。
  • 标准3敏感度93.8%,特异度48.4%。
  • 标准4敏感度92.5%,特异度87.4%。
  • 标准3和标准4敏感度显著高于标准1和标准2(p值<0.001)。

临床应用与阅片要点

  • 在钆塞酸增强MRI阅片时,可将肝胆期低信号作为廓清的替代指标用于肝细胞癌诊断。
  • 应用肝胆期低信号诊断肝细胞癌时,需结合辅助征象并排除LR-1/2/M结节以提高特异度。
  • 原文结论指出,肝胆期低信号在排除良性或非肝细胞癌恶性结节后可作为廓清的替代。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: To validate new diagnostic criteria for hepatocellular carcinoma (HCC) on gadoxetic acid-enhanced MR imaging (Gd-EOB-MRI) using hypointensity on the hepatobiliary phase (HBP) as an alternative to washout in combination with ancillary features.

METHODS: This retrospective study included 288 patients at high risk for HCC with 387 nodules (HCCs, n=292; non-HCCs, n=95) showing arterial phase hyper-enhancement (APHE) ≥1 cm on Gd-EOB-MRI. Imaging diagnoses of HCCs were made using different criteria: APHE plus hypointensity on the portal venous phase (PVP) (criterion 1), APHE plus hypointensity on the PVP and/or transitional phase (TP) (criterion 2), APHE plus hypointensity on the PVP and/or TP and/or HBP (criterion 3), and criterion 3 plus non-LR-1/2/M according to the Liver Imaging Reporting and Data System (LI-RADS) v2017 considering ancillary features (criterion 4). Sensitivities and specificities of those criteria were compared using McNemar's test.

RESULTS: Among diagnostic criteria for HCCs, criteria 3 and 4 showed significantly higher sensitivities (93.8% and 92.5%, respectively) than criteria 1 and 2 (70.9% and 86.6%, respectively) (p values <0.001). The specificity of criterion 4 (87.4%) was shown to be significantly higher than that of criterion 3 (48.4%, p<0.001), albeit comparable to criterion 2 (86.3%, p>0.999) and significantly lower than criterion 1 (97.9%, p=0.002).

CONCLUSIONS: In the non-invasive diagnosis of HCCs on Gd-EOB-MRI, HBP hypointensity may be used as an alternative to washout enabling a highly sensitive diagnosis with little loss in specificity if it is used after excluding nodules considered to be benignities or non-HCC malignancies based on characteristic imaging features.

KEY POINTS: • Gd-EOB-MRI enhancement and ancillary features can be used to diagnose HCC. • Exclusion of LR-1/2/M improves specificity when HBP hypointensity is used.

来源:Eur Radiol,查看原文。版权归原作者所有。

引用

  1. Joo I, Lee JM, Lee DH, et al. Retrospective validation of a new diagnostic criterion for hepatocellular carcinoma on gadoxetic acid-enhanced MRI: can hypointensity on the hepatobiliary phase be used as an alternative to washout with the aid of ancillary features? Eur Radiol. 2018. PMID: 30255250. doi:10.1007/s00330-018-5727-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。